In a bid to give its Japan business a big push, Lupin will launch 10 products in Japan during 2011-12.
It has a combined market size of around $2.8 billion (around Rs 12,600 crore) which is the highest number of product launch so far by the company in the world's second largest pharmaceutical market valued at $75 billion (Rs 3,38,000 crore).
"We launched five products in current year, of which four were launched recently in November," said Vinod Dhawan, president, Asia, Africa, Middle East and Latin America and business development, Lupin.
The products will be in cardiovascular, central nervous system and some other related categories.
Lupin operates through its wholly owned subsidiary Kyowa in Japan, which is the third largest country in terms of revenue generation after US and India.
During 2009-10, Kyowa launched six new products and filed applications for additional 8 products.
The pharma major, which saw consolidated net sales of Rs 4,740 crore in 2009-10, will shortly enter into oncology segment in Japan by inking strategic alliances with the companies.
"The talks are in the final stages with companies, which are based out of Japan," said Dhawan.
As per the deal, Lupin will source product from the companies based out Japan and market the products in Japan.
Dhavan expects Kyowa, which contributes around 11% to Lupin's revenue, to outperform local pharma market in terms of growth.